Is IVF DHEA safe?
As an assisted reproductive technology, IVF has helped many infertile couples realize their reproductive dreams. In the process of IVF, some adjuvant drugs are also widely used, including dehydroepiandrosterone (DHEA). However, the safety of DHEA in IVF treatment has been controversial. This article will elaborate on the safety of IVF DHEA from many aspects.
Safety assessment
First, the safety of IVF DHEA needs to be comprehensively evaluated in a qualified hospital. Many hospitals and research institutions have conducted a number of studies to evaluate the safety of DHEA in IVF. For example, a study by the University of Chicago in the United States found that there was no obvious adverse reaction in the treatment of test tube infants using DHEA. In addition, a study conducted by the University of Sydney in Australia has reached a similar conclusion, and the safety of DHEA in IVF treatment has been verified.
Secondly, the safety of IVF DHEA needs to be evaluated according to individual differences. Each patient's physical condition and physiological characteristics are different, so the safety of using DHEA will vary from person to person. Under the guidance of doctors, detailed assessment and monitoring can help determine which patients are suitable for DHEA and ensure its safety.
In addition, the dose and use time of test tube infant DHEA are also important factors affecting the safety. A study published in the journal Human Reproduction shows that monitoring and adjusting the dose of DHEA can reduce the risk of adverse reactions in patients. Therefore, before using DHEA, doctors will develop personalized treatment plans according to the specific conditions of patients to ensure their safety.
Potential risks and side effects
Although IVF DHEA is considered as a relatively safe adjuvant, there are still some potential risks and side effects.
First, DHEA may affect the hormone level of patients. A study published in the European Journal of Human Reproduction and Reproduction found that DHEA can cause a significant increase in estrogen and luteinizing hormone, which may lead to an increased risk of ovarian hyperstimulation syndrome (OHSS). Therefore, the use of DHEA should be cautious for patients at risk of ovarian stimulation.
Secondly, the long-term use of DHEA may have a potential impact on the hormone balance and health of patients. A study published in the journal Human Reproduction shows that long-term use of DHEA may affect the thyroid function of patients, leading to abnormal thyroid function. In addition, DHEA may also affect the blood lipid and blood sugar levels of patients, thus increasing the risk of cardiovascular disease and diabetes.
Finally, the use of DHEA may have adverse effects on the interaction with other drugs. Some studies have found that DHEA may interact with some drugs to affect their efficacy. Therefore, before using DHEA, the patient needs to inform the doctor of other drugs being used so that the doctor can adjust the treatment plan according to individual conditions.
Summary
To sum up, test tube infant DHEA can be considered as a relatively safe adjuvant after comprehensive evaluation in a qualified hospital. However, it is still necessary to evaluate according to individual differences, and strictly control the dosage and use timing. At the same time, patients need to understand the potential risks and side effects in order to make informed decisions. When receiving IVF treatment, full communication and consultation with doctors is an important step to ensure safety.
